HRP20171301T1 - Antitumorske kombinacije koje sadrže citarabin i protutijela koja specifično prepoznaju cd38 - Google Patents
Antitumorske kombinacije koje sadrže citarabin i protutijela koja specifično prepoznaju cd38 Download PDFInfo
- Publication number
- HRP20171301T1 HRP20171301T1 HRP20171301TT HRP20171301T HRP20171301T1 HR P20171301 T1 HRP20171301 T1 HR P20171301T1 HR P20171301T T HRP20171301T T HR P20171301TT HR P20171301 T HRP20171301 T HR P20171301T HR P20171301 T1 HRP20171301 T1 HR P20171301T1
- Authority
- HR
- Croatia
- Prior art keywords
- antibody
- seq
- amino acid
- nos
- combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
Claims (19)
1. Farmaceutska kombinacija koja sadrži protutijelo koje specifično prepoznaje CD38 i barem citarabin, naznačena time da navedeno protutijelo je sposobno uništavati D38+ stanicu pomoću apoptoze, stanične citotoksičnosti ovisne o protutijelima (ADCC), i citotoksičnosti ovisne o komplementu (CDC).
2. Kombinacija prema zahtjevu 1, naznačena time da navedeno protutijelo je humanizirano protutijelo.
3. Kombinacija prema zahtjevu 1 ili zahtjevu 2, naznačena time da je navedeno protutijelo humanizirano protutijelo proizvedeno pomoću resurfacinga.
4. Kombinacija prema zahtjevu 2 ili zahtjevu 3 naznačena time da navedeno protutijelo sadrži jednu ili više regija koje određuju komplementarnost koje imaju sekvencu aminokiseline odabranu iz skupine koju čine SEQ ID NOS: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 i 36.
5. Kombinacija prema zahtjevu 2 ili zahtjevu 3, naznačena time da je navedeno protutijelo humanizirana verzija mišjeg protutijela 38SB19, pri čemu teški lanac navedenog mišjeg protutijela 38SB19 sadrži tri uzastopne regije koje određuju komplementarnost koje imaju sekvence aminokiselina prikazane sa SEQ ID NOS: 13, 14, i 15, te pri čemu laki lanac navedenog protutijela 38SB19 sadrži tri uzastopne regije koje određuju komplementarnost koje imaju sekvence aminokiselina prikazane sa SEQ ID NOS: 16, 17, i 18.
6. Kombinacija prema zahtjevu 5, naznačena time da je navedeno protutijelo 38SB19 protutijelo proizvedeno pomoću hibridoma pohranjenog u American Type Culture Collection pod pristupnim brojem PTA-7670.
7. Kombinacija prema bilo kojem od zahtjeva 1 do 4 naznačena time da navedeno protutijelo sadrži barem jedan teški lanac i barem jedan laki lanac, pri čemu navedeni teški lanac sadrži sekvencu aminokiseline prikazanu sa SEQ ID NO: 66 i/ili navedeni teški lanac sadrži tri uzastopne regije koje određuju komplementarnost koje imaju sekvence aminokiselina prikazane sa SEQ ID NOS: 13, 14, i 15, te pri čemu navedeni laki lanac sadrži sekvencu aminokiseline odabranu iz skupine koju čine SEQ ID NOS: 62 i 64, i/ili navedeni laki lanac sadrži tri uzastopne regije koje određuju komplementarnost koje imaju sekvence aminokiselina prikazane sa SEQ ID NOS: 16, 17, i 18.
8. Kombinacija prema bilo kojem od zahtjeva 1 do 4 naznačena time da navedeno protutijelo sadrži barem jedan teški lanac i barem jedan laki lanac, pri čemu navedeni teški lanac ima sekvencu aminokiseline prikazanu sa SEQ ID NO: 72 i/ili navedeni teški lanac sadrži tri uzastopne regije koje određuju komplementarnost koje imaju sekvence aminokiselina prikazane sa SEQ ID NOS: 25, 26, i 27, te pri čemu navedeni laki lanac ima sekvencu aminokiseline odabranu iz skupine koju čine SEQ ID NOS: 68 i 70 i/ili navedeni laki lanac sadrži tri uzastopne regije koje određuju komplementarnost koje imaju sekvence aminokiselina prikazane sa SEQ ID NOS: 28, 29, i 30.
9. Farmaceutska kombinacija prema bilo kojem od zahtjeva 1 do 8, naznačena time da navedena farmaceutska kombinacija je farmaceutski pripravak koji sadrži navedeno anti-CD38 protutijelo u kombinaciji s citarabinom.
10. Farmaceutska kombinacija prema zahtjevu 1 naznačena time da je za upotrebu za liječenje raka.
11. Kombinacija za upotrebu prema zahtjevu 10, naznačena time da navedeno protutijelo je humanizirano protutijelo.
12. Kombinacija za upotrebu prema zahtjevu 10 ili zahtjevu 11, naznačena time da navedeno protutijelo je humanizirano protutijelo proizvedeno pomoću resurfacinga.
13. Kombinacija za upotrebu prema zahtjevu 11 ili zahtjevu 12, naznačena time da navedeno protutijelo je humanizirana verzija mišjeg protutijela 38SB19, pri čemu teški lanac navedenog mišjeg protutijela 38SB19 sadrži tri uzastopne regije koje određuju komplementarnost koje imaju sekvence aminokiselina prikazane sa SEQ ID NOS: 13, 14, i 15, te pri čemu laki lanac navedenog protutijela 38SB19 sadrži tri uzastopne regije koje određuju komplementarnost koje imaju sekvence aminokiselina prikazane sa SEQ ID NOS: 16, 17, i 18.
14. Kombinacija za upotrebu prema zahtjevu 13, naznačena time da navedeno 38SB19 protutijelo je protutijelo proizvedeno pomoću hibridoma pohranjenog u American Type Culture Collection pod pristupnim brojem PTA-7670.
15. Kombinacija za upotrebu prema zahtjevu 10 naznačena time da navedeno protutijelo sadrži jednu ili više regija koje određuju komplementarnost koje imaju sekvencu aminokiseline odabranu iz skupine koju čine SEQ ID NOS: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 i 36.
16. Kombinacija za upotrebu prema zahtjevu 13 naznačena time da navedeno protutijelo sadrži barem jedan teški lanac i barem jedan laki lanac, pri čemu navedeni teški lanac sadrži sekvencu aminokiseline prikazanu sa SEQ ID NO: 66 i/ili navedeni teški lanac sadrži tri uzastopne regije koje određuju komplementarnost koje imaju sekvence aminokiselina prikazane sa SEQ ID NOS: 13, 14, i 15, te pri čemu navedeni laki lanac sadrži sekvencu aminokiseline odabranu iz skupine koju čine SEQ ID NOS: 62 i 64 i/ili navedeni laki lanac sadrži tri uzastopne regije koje određuju komplementarnost koje imaju sekvence aminokiselina prikazane sa SEQ ID NOS: 16, 17, i 18.
17. Kombinacija za upotrebu prema zahtjevu 13 naznačena time da navedeno protutijelo sadrži barem jedan teški lanac i barem jedan laki lanac, pri čemu navedeni teški lanac sadrži sekvencu aminokiseline prikazanu sa SEQ ID NO: 72 i/ili navedeni teški lanac sadrži tri uzastopne regije koje određuju komplementarnost koje imaju sekvence aminokiselina prikazane sa SEQ ID NOS: 25, 26, i 27, te pri čemu navedeni laki lanac sadrži sekvencu aminokiseline odabranu iz skupine koju čine SEQ ID NOS: 68 i 70 i/ili navedeni laki lanac sadrži tri uzastopne regije koje određuju komplementarnost koje imaju sekvence aminokiselina prikazane sa SEQ ID NOS: 28, 29, i 30.
18. Kombinacija prema zahtjevu 9 ili za upotrebu prema zahtjevima 10-15, naznačena time da su sastojci navedene kombinacije za odvojenu primjenu.
19. Kombinacija prema zahtjevu 9 ili za upotrebu prema zahtjevima 10-15, naznačena time da su sastojci navedene kombinacije za istovremenu primjenu.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08291118A EP2191842A1 (en) | 2008-11-28 | 2008-11-28 | Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine |
| EP09775304.0A EP2370096B1 (en) | 2008-11-28 | 2009-11-27 | Antitumor combinations containing cytarabine and antibodies recognizing specifically cd38 |
| PCT/IB2009/055391 WO2010061359A1 (en) | 2008-11-28 | 2009-11-27 | Antitumor combinations containing antibodies recognizing specifically cd38 and cytarabine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20171301T1 true HRP20171301T1 (hr) | 2017-10-20 |
Family
ID=40627502
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20171301TT HRP20171301T1 (hr) | 2008-11-28 | 2009-11-27 | Antitumorske kombinacije koje sadrže citarabin i protutijela koja specifično prepoznaju cd38 |
Country Status (40)
| Country | Link |
|---|---|
| US (1) | US20120093806A1 (hr) |
| EP (2) | EP2191842A1 (hr) |
| JP (2) | JP2012510463A (hr) |
| KR (1) | KR101715958B1 (hr) |
| CN (2) | CN102264386A (hr) |
| AR (1) | AR073425A1 (hr) |
| AU (1) | AU2009321251B2 (hr) |
| BR (1) | BRPI0921858B1 (hr) |
| CA (1) | CA2745005C (hr) |
| CL (1) | CL2011001232A1 (hr) |
| CO (1) | CO6440556A2 (hr) |
| CR (1) | CR20110282A (hr) |
| DK (1) | DK2370096T5 (hr) |
| EA (1) | EA027070B1 (hr) |
| EC (1) | ECSP11011071A (hr) |
| ES (1) | ES2638926T3 (hr) |
| HN (1) | HN2011001423A (hr) |
| HR (1) | HRP20171301T1 (hr) |
| HU (1) | HUE035910T2 (hr) |
| IL (2) | IL213118A (hr) |
| LT (1) | LT2370096T (hr) |
| MA (1) | MA32899B1 (hr) |
| MX (1) | MX344973B (hr) |
| NI (1) | NI201100107A (hr) |
| NZ (1) | NZ593085A (hr) |
| PA (1) | PA8849901A1 (hr) |
| PE (1) | PE20120205A1 (hr) |
| PL (1) | PL2370096T3 (hr) |
| PT (1) | PT2370096T (hr) |
| PY (1) | PY09043372A (hr) |
| RS (1) | RS56248B1 (hr) |
| SG (1) | SG171821A1 (hr) |
| SI (1) | SI2370096T1 (hr) |
| SM (1) | SMT201700403T1 (hr) |
| TN (1) | TN2011000242A1 (hr) |
| TW (1) | TWI436770B (hr) |
| UA (1) | UA104160C2 (hr) |
| UY (1) | UY32266A (hr) |
| WO (1) | WO2010061359A1 (hr) |
| ZA (1) | ZA201104064B (hr) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2191842A1 (en) * | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine |
| SI2621531T1 (sl) | 2010-09-27 | 2017-06-30 | Morphosys Ag | Anti-cd38 protitelo in lenalidomid ali bortezomib za zdravljenje multiplega mieloma in nhl |
| UA112170C2 (uk) * | 2010-12-10 | 2016-08-10 | Санофі | Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб |
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| JP6426093B2 (ja) | 2012-09-25 | 2018-11-28 | モルフォシス・アーゲー | 組み合わせ及びその使用 |
| JP6279065B2 (ja) * | 2013-03-13 | 2018-02-14 | サノフイ | 抗ｃｄ３８抗体およびカーフィルゾミブを含む組成物 |
| SG10201803288RA (en) | 2013-10-31 | 2018-05-30 | Sanofi Sa | Specific anti-cd38 antibodies for treating human cancers |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| MX386886B (es) | 2014-09-09 | 2025-03-12 | Janssen Biotech Inc | Combinación de anticuerpos anti-cd38 y ácido todo-trans retinoico para usarse en terapias. |
| AU2015358615B2 (en) | 2014-12-04 | 2021-08-05 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute myeloid leukemia |
| MX389805B (es) | 2015-05-20 | 2025-03-11 | Janssen Biotech Inc | Anticuerpos anti-cd38 para el tratamiento de amiloidosis de cadena ligera y otras enfermedades malignas hematológicas positivas para cd38. |
| AU2016282674B2 (en) | 2015-06-22 | 2022-01-13 | Janssen Biotech, Inc. | Combination therapies for heme malignancies with anti-CD38 antibodies and survivin inhibitors |
| US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
| WO2017048872A1 (en) * | 2015-09-14 | 2017-03-23 | Leukemia Therapeutics, LLC | Identification of novel diagnostics and therapeutics by modulating rhoh |
| DK3827845T3 (da) | 2015-11-03 | 2022-05-23 | Janssen Biotech Inc | Subkutane formuleringer af anti-cd38-antistoffer og anvendelser deraf |
| US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
| JP2019527678A (ja) | 2016-06-28 | 2019-10-03 | ユーエムセー・ユトレヒト・ホールディング・ベー・フェー | ＣＤ３８に特異的に結合する抗体によるＩｇＥ媒介疾患の治療 |
| MA45674A (fr) | 2016-07-15 | 2019-05-22 | Takeda Pharmaceuticals Co | Méthodes et matériaux permettant d'évaluer une réponse à des traitements de déplétion de plasmoblastes et de plasmocytes |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| JP2021502961A (ja) | 2017-10-31 | 2021-02-04 | ヤンセン バイオテツク，インコーポレーテツド | 高リスク多発性骨髄腫の治療方法 |
| KR20210006321A (ko) | 2018-01-12 | 2021-01-18 | 다케다 야쿠힌 고교 가부시키가이샤 | 항-cd38 항체의 피하 투여 |
| EP3938394A1 (en) | 2019-03-15 | 2022-01-19 | MorphoSys AG | Anti-cd38 antibodies and pharmaceutical compositions thereof for the treatment of autoantibody-mediated autoimmune disease |
| US11655302B2 (en) | 2019-06-10 | 2023-05-23 | Sanofi | Anti-CD38 antibodies and formulations |
| CN112876563B (zh) * | 2019-11-29 | 2022-08-16 | 康诺亚生物医药科技（成都）有限公司 | 药物组合物及其制备方法和应用 |
| MX2022006882A (es) | 2019-12-05 | 2022-11-08 | Sanofi Aventis Us Llc | Formulaciones de anticuerpos anti-cd38 para administracion subcutanea. |
| WO2022152823A1 (en) | 2021-01-14 | 2022-07-21 | Morphosys Ag | Anti-cd38 antibodies and their uses |
| TW202302642A (zh) | 2021-03-01 | 2023-01-16 | 德商莫菲西斯公司 | 用於治療抗體介導移植物排斥用途之抗ｃｄ３８抗體 |
| CN113278075B (zh) * | 2021-06-18 | 2021-12-14 | 芜湖森爱驰生物科技有限公司 | 一种炎症检测试剂盒 |
| TW202321303A (zh) | 2021-07-19 | 2023-06-01 | 德商莫菲西斯公司 | 抗pla2r自體抗體媒介膜性腎病變之治療 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| EP1690934A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| EP1500329B1 (en) | 1996-12-03 | 2012-03-21 | Amgen Fremont Inc. | Human antibodies that specifically bind human TNF alpha |
| BRPI9809391B8 (pt) | 1997-04-14 | 2021-05-25 | Amgen Res Munich Gmbh | processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| WO1999062526A2 (en) * | 1998-06-05 | 1999-12-09 | Mayo Foundation For Medical Education And Research | Use of genetically engineered antibodies to cd38 to treat multiple myeloma |
| US20080057070A1 (en) * | 2004-11-04 | 2008-03-06 | Chiron Corporation | Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use |
| EP2567976B1 (en) * | 2005-03-23 | 2017-07-19 | Genmab A/S | Antibodies against CD38 for treatment of multiple myeloma |
| EP3569245A1 (en) * | 2006-09-26 | 2019-11-20 | Genmab A/S | Combination treatment of cd38-expressing tumors |
| EP1914242A1 (en) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| WO2009094391A1 (en) * | 2008-01-23 | 2009-07-30 | Xencor, Inc. | Optimized cd40 antibodies and methods of using the same |
| EP2191842A1 (en) * | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine |
-
2008
- 2008-11-28 EP EP08291118A patent/EP2191842A1/en not_active Ceased
-
2009
- 2009-11-25 AR ARP090104547A patent/AR073425A1/es not_active Application Discontinuation
- 2009-11-25 PA PA20098849901A patent/PA8849901A1/es unknown
- 2009-11-25 UY UY0001032266A patent/UY32266A/es not_active Application Discontinuation
- 2009-11-25 PY PY200909043372A patent/PY09043372A/es unknown
- 2009-11-25 TW TW098140152A patent/TWI436770B/zh active
- 2009-11-27 UA UAA201108055A patent/UA104160C2/uk unknown
- 2009-11-27 EP EP09775304.0A patent/EP2370096B1/en active Active
- 2009-11-27 ES ES09775304.0T patent/ES2638926T3/es active Active
- 2009-11-27 JP JP2011538094A patent/JP2012510463A/ja not_active Withdrawn
- 2009-11-27 PL PL09775304T patent/PL2370096T3/pl unknown
- 2009-11-27 BR BRPI0921858-0A patent/BRPI0921858B1/pt active IP Right Grant
- 2009-11-27 MX MX2011005666A patent/MX344973B/es active IP Right Grant
- 2009-11-27 PE PE2011001097A patent/PE20120205A1/es not_active Application Discontinuation
- 2009-11-27 HR HRP20171301TT patent/HRP20171301T1/hr unknown
- 2009-11-27 HU HUE09775304A patent/HUE035910T2/en unknown
- 2009-11-27 KR KR1020117014748A patent/KR101715958B1/ko active Active
- 2009-11-27 PT PT97753040T patent/PT2370096T/pt unknown
- 2009-11-27 NZ NZ593085A patent/NZ593085A/xx not_active IP Right Cessation
- 2009-11-27 WO PCT/IB2009/055391 patent/WO2010061359A1/en not_active Ceased
- 2009-11-27 SI SI200931726T patent/SI2370096T1/sl unknown
- 2009-11-27 EA EA201100868A patent/EA027070B1/ru not_active IP Right Cessation
- 2009-11-27 SM SM20170403T patent/SMT201700403T1/it unknown
- 2009-11-27 RS RS20170860A patent/RS56248B1/sr unknown
- 2009-11-27 CN CN2009801481843A patent/CN102264386A/zh active Pending
- 2009-11-27 CA CA2745005A patent/CA2745005C/en not_active Expired - Fee Related
- 2009-11-27 SG SG2011037975A patent/SG171821A1/en unknown
- 2009-11-27 AU AU2009321251A patent/AU2009321251B2/en active Active
- 2009-11-27 CN CN201710103901.7A patent/CN107096022A/zh active Pending
- 2009-11-27 DK DK09775304.0T patent/DK2370096T5/en active
- 2009-11-27 LT LTEP09775304.0T patent/LT2370096T/lt unknown
- 2009-11-27 US US13/130,867 patent/US20120093806A1/en not_active Abandoned
-
2011
- 2011-05-17 TN TN2011000242A patent/TN2011000242A1/fr unknown
- 2011-05-23 EC EC2011011071A patent/ECSP11011071A/es unknown
- 2011-05-24 IL IL213118A patent/IL213118A/en active IP Right Grant
- 2011-05-24 IL IL213115A patent/IL213115A/en active IP Right Grant
- 2011-05-26 CR CR20110282A patent/CR20110282A/es unknown
- 2011-05-26 CL CL2011001232A patent/CL2011001232A1/es unknown
- 2011-05-27 HN HN2011001423A patent/HN2011001423A/es unknown
- 2011-05-27 NI NI201100107A patent/NI201100107A/es unknown
- 2011-05-27 CO CO11065641A patent/CO6440556A2/es unknown
- 2011-06-01 ZA ZA2011/04064A patent/ZA201104064B/en unknown
- 2011-06-13 MA MA33941A patent/MA32899B1/fr unknown
-
2015
- 2015-06-01 JP JP2015111127A patent/JP6072854B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20171301T1 (hr) | Antitumorske kombinacije koje sadrže citarabin i protutijela koja specifično prepoznaju cd38 | |
| HRP20130922T1 (hr) | U potpunosti humana protutijela protiv humanog 4-1bb (cd137) | |
| JP2021514664A5 (hr) | ||
| HRP20150965T1 (hr) | Anti-fgr3 protutijela i metode koje ih koriste | |
| HRP20211444T1 (hr) | Anti-dll3 antitijelo | |
| RU2014143784A (ru) | Фармацевтическая композиция для лечения и/или предотвращения рака желчного пузыря | |
| UA114879C2 (uk) | Антитіло до cd38 для лікування раку | |
| RU2013141956A (ru) | Антитело против ксф-1r | |
| JP2012510461A5 (hr) | ||
| AR074221A1 (es) | Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y ciclofosfamida | |
| IL276830B2 (en) | Anti-claudin 18.2 antibodies and uses thereof | |
| WO2008063771A3 (en) | Anti-cd20 antibodies and methods of use | |
| RU2014108047A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака поджелудочной железы | |
| NZ612055A (en) | Antitumor combinations containing antibodies recognizing specifically cd38 and bortezomib | |
| HRP20240495T1 (hr) | Anti-garp antitijelo | |
| HRP20160584T1 (hr) | Novo anti-dr5 antitijelo | |
| FI2995315T3 (fi) | Koostumuksia ja menetelmiä hematologisten syöpien hoitamiseksi kohdistuen sirp-alfan ja cd47:n interaktioon | |
| JP2017149720A5 (hr) | ||
| RU2013152164A (ru) | Анти-в7-н3-антитело | |
| FI3683235T3 (fi) | Anti-IL-33-vasta-aineita ja niiden käyttöjä | |
| NZ602892A (en) | Antibodies that bind human cd27 and uses thereof | |
| NZ595464A (en) | Alpha-4-beta-7 heterodimer specific antagonist antibody | |
| ME02807B (me) | HUMANI ANTIGEN-VEZUJUĆI PROTEINI KOJI SE VEZUJU ZA BETA-KLOTHO, FGF RECEPTORE l NJIHOVE KOMPLEKSE | |
| RU2014120757A (ru) | Связывающие молекулы, специфичные по отношению к her3, и их применения | |
| RU2014138039A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака |